Navigation Links
Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
Date:4/23/2009

ANA773 and two receiving placebo in each cohort. There was a statistically significant decrease in viral load in the group dosed at 1600 mg compared to placebo, although not all patients at this dose demonstrated a decrease in viral load. One patient at 1600 mg demonstrated a nadir response of 0.8 log10 decline with an end-of-treatment response of 0.7 log10; a second patient demonstrated a nadir response of 1.1 log10 decline and an end-of-treatment response of 0.5 log10; and a third patient demonstrated a nadir response of 2.5 log10 decline and an end-of-treatment response of 2.2 log10. No serious adverse events have been reported and there were no discontinuations from the patient portion of this study. In an earlier segment of the study, dosing in healthy volunteers showed evidence of immune induction starting at 800 mg. Tolerability in healthy volunteers was generally good, with no serious adverse events. An increased incidence of interferon-like side effects was seen at the 1200 and 1600 mg dose levels, with one discontinuation at 1200 mg and two discontinuations at 1600 mg. The pharmacokinetic (PK) and pharmacodynamic (PD) data from the healthy volunteer portion of the Phase I Clinical Trial of ANA773 in HCV are being presented in a poster at EASL titled, "PK/PD Assessment of a Phase I Healthy Volunteer with ANA773, an Oral Inducer of Endogenous Interferons that Acts Via TLR7, for the Treatment of HCV."

  • Phase I Clinical Trial in Oncology. Anadys continues to enroll patients in a Phase I study of ANA773 in oncology. The Company is currently dosing ANA773 at 800 mg, administered every other day.

Webcast of Conference Call

Anadys will host a conference call at 5:00 pm Eastern Daylight Time today to discuss its first quarter 2009 financial results and highlights and to provide an update on its deve
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... , July 27, 2015 /PRNewswire/ - Quest PharmaTech ... company developing and commercializing products for the treatment of ... Quest announces that it has closed a $1,000,000 unit ... placement of 16,666,667 units of the Company at a ... of one common share and one common share purchase ...
(Date:7/27/2015)...   Inocucor Technologies Inc ., the agriculture ... farmers, has received a notice of allowance from ... patent application to protect Inocucor consortia and unique ... yields on farms and in greenhouses. ... microbial consortium and its fermentation byproducts, which are ...
(Date:7/27/2015)... The Brain & Behavior Research ... annual Klerman and Freedman Prizes, recognizing exceptional clinical ... supported by NARSAD Young Investigator Grants. The grants ... in neurobiological and psychosocial research, garner pilot data ... detection, treatment, prevention and cure of mental illnesses. ...
(Date:7/26/2015)... ... July 26, 2015 , ... Maine ... calibration verification / linearity test kit. The VALIDATE® ANEMIA kit contains Ferritin, Folate, ... is prepared using the CLSI recommended “equal delta” method for linearity testing and ...
Breaking Biology Technology:Quest PharmaTech Closes $1,000,000 Private Placement 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 4Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 5Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 6Maine Standards Company, LLC Announces Release of VALIDATE® ANEMIA Calibration Verification / Linearity Test Kit 2
... YORK, March 5 Bristol-Myers Squibb,Company (NYSE: ... of Directors,has elected Jean-Marc Huet senior vice president ... this role, Mr. Huet will be,responsible for directing ... the global financial operations of the organization and ...
... projects ONOM@TOPIC and SilOnIS shared ... the most innovative and sustainable project in ... European smartcard platform for,citizenship and mobile multimedia ... secure for users,while adding value for network ...
... March 4 On Wednesday, March 5, 2008,at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 ... CTIC),management team will host a conference call to discuss the company,s recent,transactions targeting cleaning ... ... ...
Cached Biology Technology:Bristol-Myers Squibb Board Elects Jean-Marc Huet Senior Vice President and Chief Financial Officer 2Bristol-Myers Squibb Board Elects Jean-Marc Huet Senior Vice President and Chief Financial Officer 3MEDEA+ Noblanc award highlights improvements in microelectronics 2MEDEA+ Noblanc award highlights improvements in microelectronics 3Cell Therapeutics, Inc. to Hold Conference Call to Update on Recent Transactions and Upcoming Milestones 2
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. ... a biometric authentication company focused on the growing ... smart wallet, announces that it has filed provisional ... and Method. This invention highlights ... only authorizes an account, but also the user ...
(Date:7/13/2015)... , Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION ... new convenient and secure method to make payments.  ... payment methods, introduced with its groundbreaking voice-direct payment ...
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. ... of human interface solutions, today announced a ... first fully hardware encapsulated fingerprint sensor and ... technology is literally off the grid, isolating ... matching within the fingerprint sensor to provide ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... people are biologically more susceptible to drug addiction than others, ... In the August 15, 2007 issue of the Journal of ... study that may help answer this question. ... had a particular receptor in the brain that is more ...
... August 15, 2007) A prominent problem in AIDS ... to concentrate and perform normal movements. Scientists at ... how HIV/AIDS disrupts the normal replication of stem cells ... forming. Drs. Stuart Lipton, Marcus Kaul, Shu-ichi Okamoto ...
... reported new insight into the pathology underlying a ... that is caused by alterations in the same ... tremor/ataxia syndrome (FXTAS) overwhelmingly affects males, usually in ... In contrast, fragile X syndrome manifests itself from ...
Cached Biology News:Nicotinic receptors may be important targets for treatment of multiple addictions 2AIDS interferes with stem cells in the brain 2AIDS interferes with stem cells in the brain 3Deep into the machinery of adult fragile X 2Deep into the machinery of adult fragile X 3